Doctors must now prescribe drugs using their chemical name, not brand names. That’s good news for patients



Shuterstock

Matthew Grant, Monash University

From today (February 1), when you receive a prescription in Australia, it will list the name of the medication’s active ingredient rather than the brand name. So, for example, instead of receiving a prescription for Ventolin, your script will say “salbutamol”.

This national legislation change, called active ingredient prescribing, is long overdue for Australian health care.

Using the name of the drug — instead of the brand name, of which there are often many — will simplify how we talk about and use medications.

This could have a range of benefits, including fewer medication errors by both doctors and patients.

What is an active ingredient?

The active ingredient describes the main chemical compound in the medicine that affects your body. It’s the ingredient that helps control your asthma or headache, for example.

Drugs are tested to ensure they contain exactly the same active ingredients regardless of which brand you buy.

There’s only one active ingredient name for each type of medical compound, although they may come in different strengths. Some types of medications may contain multiple active ingredients, such as Panadeine Forte, which contains both paracetamol and codeine.




Read more:
Prescribing generic drugs will reduce patient confusion and medication errors


There can be several brand names

Until now, doctors and other prescribers have used a mixture of brand and active ingredient names when prescribing medicines. An Australian study found doctors used brand names for 80.5% of prescriptions.

Different brands are available for most medications — up to 12 for some. Combined with active ingredient names, this equates to thousands of different names — too many for any patient, doctor, nurse or pharmacist to remember.

A senior man taking a tablet. There are a variety of medications on the table.
Older people are at higher risk of making medication errors, as they tend to take more medications.
Shutterstock

Here’s an example of the problem.

I ask John, a patient whom I’ve just met, whether he takes cholesterol medications, commonly called statins. The active ingredient names for this group of medications all end in “statin” (for example, pravastatin, simvastatin).

“Ummm, I’m not sure, is it a blue pill?” John asks.

“It could come in many colours. It might be called atorvastatin, or Lipitor,” I reply. “Perhaps rosuvastatin, or Crestor, or Zocor?”

“Ah yes, Crestor, I am taking that,” John exclaims, after deliberating for some time.

This is a common and important conversation, but could be simpler for both of us if John was familiar with the active ingredient name.

And while we did eventually come to the answer, this medication could have easily been overlooked, by both John and myself. This may have significant implications and interact with other medicines I might prescribe.




Read more:
I’ve heard COVID is leading to medicine shortages. What can I do if my medicine is out of stock?


Cause for confusion

The main problem with using brand names for medications is the potential for confusion, as we see with John.

A prescription written using a brand name doesn’t mean you can’t buy other brands. And your pharmacist may offer to substitute the brand specified for an equivalent generic drug. So, people often leave the pharmacy with a medication name or package that bears no resemblance to the prescription.

When the terms we use to describe medicines in conversation, on prescriptions and what’s written on the medication packet can all be different, patients might not understand which medications they’re taking, or why.

This often leads to doubling up (taking two brands of the same medication), or forgetting to take a certain medication because the name on the package doesn’t match what’s written on your medication list or prescription.

Confusion resulting from using brand names has been associated with serious medication errors, including overdoses. Elderly people are the most susceptible, as they’re most likely to take multiple medications.

Even when the confusion doesn’t cause harm, it can be problematic in other ways. If patients don’t understand their medicines, they may be less likely to be proactive in making decisions with their doctor or pharmacist about their health care.

Health professionals can also get confused, potentially leading to prescribing errors.

What are the benefits of active ingredient prescribing?

The main benefit of the switch is to simplify the language around medications.

Once we become accustomed to using one standardised name for each medicine, it will be easier to talk about medicines, whether with a family member, pharmacist or doctor.

The better we understand the medications we’re using, the fewer errors we make, and the more control we can take over our medication use and decisions.

A pharmacist studies a woman's prescription.
A pharmacist can let you know which brands of your medication are are available.
Shutterstock

This change will also serve to promote choice.

When you’re prescribed a medicine with a certain name, you’re more likely to buy that brand. In some cases there may be generic medicines that are cheaper and just as effective. Or there may be other forms of the medication that better suit your needs, such as a capsule only available in another brand.

Not too much will change

This new rule is not expected to lead to extra work for doctors, pharmacists or other health professionals who prescribe medicines, as most clinical software will make the transition automatically.

Doctors can elect to still include the brand name on the prescription, if they feel it’s important for the patient. But aside from some limited exceptions, the active ingredient name will need to be listed, and will be listed first.

Some active ingredient names may be a bit longer and more complex than certain brand names, so there might be a period of adjustment for consumers.

But in the long term, this change will streamline terminology around medicines and make things easier, and hopefully safer, for everyone.

Next time you receive your prescription, have a look at the name of the active ingredient. Remember it, and use that name when you talk to your family, doctor and pharmacist.




Read more:
Boomers have a drug problem, but not the kind you might think


The Conversation


Matthew Grant, Palliative Medicine Physician, Research Fellow, Monash University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

With Syria missile strikes, Trump turns from non-intervention to waging war



Image 20170407 16680 mc9rri
Military strikes against a Syrian airforce base mark Donald Trump’s first big foreign policy test as president.
Reuters/Carlos Barria

Ben Rich, Curtin University

The United States’ unilateral missile strikes against a Syrian airforce base are a dramatic escalation of its participation in that country’s civil war. The US government has attacked a Syrian government asset for the first time. The Conversation

The attack also marks Donald Trump’s first major foreign policy test as US president. It represents a 180-degree shift from his previous position of opposing intervention in Syria. And the sudden about-face sends a worrying signal for how his administration may handle future crises in international relations.

The operation

On Thursday, the US unilaterally launched strikes against the al-Shayrat airforce base in Homs. This base primarily houses Mig-23 and SU-22 strike craft and Mig-25 interceptors.

The attack consisted of 59 sea-launched Tomahawk cruise missiles, which targeted airframes and supporting infrastructure. It reportedly led to casualties among Syrian military personnel.

Unlike the actions of his predecessor, Barack Obama, prior to the 2012 Libya intervention, Trump sought no international legal sanction for the strike.

The attack has been justified as a punitive response to the Syrian military’s likely use of sarin chemical nerve agents against civilians in Idlib province. This led to at least 70 deaths and drew worldwide condemnation.

The Idlib incident was a much smaller repeat of a major sarin deployment in the Damascus suburb of Ghouta in 2013. That attack led to hundreds of civilian deaths – many of them children.

The Ghouta atrocity led the US to the brink of war with Syria; the Syrian government was alleged to have crossed Obama’s infamous “red line”. Ultimately, however, diplomatic manoeuvring by senior US, Russian and Syrian officials de-escalated the situation. They were able to negotiate the apparent dismantling of Syria’s chemical weapons program.

Recent events, however, suggest this dismantling was not as extensive as previously thought.

The strikes were launched from the USS Porter.
Reuters

Trump’s humanitarian intervention?

What’s concerning is how the strikes have been rationalised. Trump has described the strikes as aimed at protecting a “vital national security interest”. However, this appears to contradict one of the fundamental themes that buoyed Trump’s rise to power.

Throughout the 2016 presidential campaign, Trump emphasised the need to embrace a transactional approach to foreign relations that placed little value on human rights.

The then-presidential candidate was criticised for appearing to be open to accommodating the anti-human-rights predilections of authoritarian rulers provided they served US economic and security interests.

Trump condemned the Obama administration’s response to the Ghouta attacks when strikes were under consideration. He explicitly and repeatedly indicated that, as president, he would adopt a non-interventionist position in Syria in spite of the humanitarian crisis.

//platform.twitter.com/widgets.js

//platform.twitter.com/widgets.js

//platform.twitter.com/widgets.js

However, the strikes clearly contradict this position. Trump now claims intervention was a matter of “vital national security interest”.

Given the Assad regime’s use of chemical weapons threatened no US citizens – nor allies – one is left to conclude that preventing further use of chemical weapons against Syrian civilians is now seen as vital to US national security.

This view is itself dubious and inconsistent with a conflict where the US has largely turned a blind eye to half-a-million dead Syrian civilians over the past six years. The US has increasingly contributed to this toll in recent weeks.

A worrying precedent

A point of concern for some has been Trump’s inability to fully grasp the consequences of his actions and his general reflexiveness to the conditions he confronts. As with many of his domestic policy promises on the campaign trail, Trump’s Syria stance appears to be a flip-flop.

Shifts in domestic and foreign policy are generally to be expected and afforded some latitude as a candidate transitions to the presidency. But the degree and speed of Trump’s foreign policy switches are of serious concern.

Unpredictability in international relations has particularly high stakes. It can lead to rapid escalations, collapse of long-term relationships and partnerships, and even war.

This is of particular concern in Syria, given the close proximity of Russian forces actively fighting to defend the Assad regime.

The US apparently ultimately alerted (telling, not asking) Russia to the strikes against the Syrian regime. Yet the speed with which such an operation was organised, along with its unilateral and non-consultative nature, does little to dispel the fears of foreign policy realists about the Trump administration’s inconsistent and chaotic approach to world affairs.

The US military’s strikes only intensify that debate. Will the system ultimately force Trump to fall in line with a more consistent and predictable approach to foreign relations? Or will the policy bedlam ultimately prove sustainable, and make unpredictability the new norm in the international system?

Ben Rich, Lecturer in International Relations and Security Studies, Curtin University

This article was originally published on The Conversation. Read the original article.

Secretary of State cites citizen media reports from Syria in criticism of attack


Gigaom

A large number of videos, photos and graphic descriptions of chemical-weapon attacks on civilians have been coming out of Syria over the past day, and it is clear they have made an impact not just on those observing the violence from afar but also on U.S. Secretary of State John Kerry, who cited them in a statement about the attack on Monday. Said Kerry:

Last night, after speaking with foreign ministers from around the world about the gravity of this situation, I went back and I watched the videos — the videos that anybody can watch in the social media, and I watched them one more gut-wrenching time. It is really hard to express in words the the human suffering that they lay out before us.

As a father, I can’t get the image out of my head of a man who held up his dead child, wailing while…

View original post 69 more words